| |
Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy [viral failure]- Time to Modify Treatment Guidelines?
|
| |
| |
First Demonstration Project of Long-Acting Injectable
Antiretroviral Therapy for Persons With and Without
Detectable Human Immunodeficiency Virus (HIV)
Viremia in an Urban HIV Clinicc - Download the PDF here
Demonstration Project of Long-Acting Antiretroviral Therapy in a
Diverse Population of People With HIV Download the PDF here
Long-acting Injectable Cabotegravir/
Rilpivirine Effective in a Small Patient
Cohort With Virologic Failure on Oral
Antiretroviral Therapy - Download the PDF here
Projected Benefits of Long-Acting Antiretroviral Therapy
in Nonsuppressed People With Human Immunodeficiency
Virus Experiencing Adherence Barriers - Download the PDF here
September 22nd, 2023
4 studies with pdfs referenced by Sax.
Just Published: Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy
Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers
Demonstration Project of Long-Acting Antiretroviral Therapy in a
Diverse Population of People With HIV
First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic
-----------------------------------
https://blogs.jwatch.org/hiv-id-observations/index.php/long-acting-cabotegravir-rilpivirine-for-people-not-taking-oral-therapy-time-to-modify-treatment-guidelines/2023/09/22/
HIV treatment guidelines are understandably reluctant to endorse practices that have limited data. Having served on two such panels (previously, DHHS and currently, the IAS-USA guidelines), I totally get this - you don't want to put a stamp of approval on strategies that may ultimately do more harm than good.
With the caveat that I cannot speak for the guidelines panel I currently serve on, I can give you my opinion on a topic much discussed among us ID and HIV specialists - namely, the use of long-acting cabotegravir and rilpivirine in people not taking standard oral ART, despite all our efforts to encourage them to do so.
Here it is:
If the alternative is untreated and progressive HIV disease, and the patient has advanced immunosuppression, we should stop discouraging use of this potentially life-saving therapy.
I base this on what are now a few published studies, including the original reports from UCSF, a follow-up from them with a larger sample size, a modeling analysis demonstrating substantial projected survival benefits, and now - just published in Clinical Infectious Diseases - a small case series from a different clinic with comparably excellent outcomes.
At a Ryan White-funded HIV clinic at the University of Mississippi Medical Center in Jackson, clinicians began offering injectable CAB/RPV in February 2022 as a salvage option to people with HIV (PWH) who had viremia despite intensive case management strategies. Since that time, they have offered it to 12 patients - 7 women, 5 men. The baseline mean CD4-cell count was 233, and HIV viral load 152,657 copies/mL, with 5 of 12 having a history of AIDS-defining opportunistic infections.
With the caveat that follow-up is necessarily short, the results were excellent: All 12 achieved viral suppression within 3 months of treatment initiation, with no virologic rebound to date. They also reported good immunologic responses and high adherence to scheduled injections. These favorable results are all the more remarkable since some of the participants had NNRTI and INSTI resistance mutations, though none had full predicted resistance to either drug.
The experience with these dozen patients is now being reproduced anecdotally in small case numbers from other centers, including our own. While San Francisco led the way, this is doable in any HIV treatment clinic with intensive case management services.
Meanwhile, the DHHS HIV treatment guidelines continue to state the following:
The long-acting ARV combination of injectable cabotegravir (CAB) and RPV is not currently recommended for people with virologic failure [DHHS].
I strongly believe the time has come for us to revise these prohibitory statements (a similar one appears in the IAS-USA guidelines). Such statements may make it difficult for clinicians to procure this treatment for PWH whose treatment options (oral ART) otherwise just aren't working. One can craft language with appropriate cautionary statements describing the unusual settings in which CAB-RPV is the best - and, importantly, the only - option for people with virologic failure.
Here's a go at this:
Under rare circumstances, long-acting CAB-RPV can be an option for people with virologic failure when no other treatment options are available or effective. Such treatment must be accompanied by intensive case management and close follow-up. It should be limited to PWH who meet the following criteria:
•Unable to or cannot take oral ART
•Are at high risk of HIV disease progression (CD4 < 200 or a prior history of AIDS-defining complications)
•Have virus susceptible to both CAB and RPV
•Can be supported by intensive case management services
Sure, there will be cases where treatment failure with resistance occurs; where patients are lost to follow-up; where we will need to battle with payers to convince them to cover this non-FDA–approved indication; where the team of people (and it's always a team) charged with case-management and medication administration spend enormous time and energy to no avail.
I acknowledge these issues and frustrations, but at the same time, ask - what is the alternative?
It can't be to withhold the only regimen that might help them. Because as shown in the figure posted below, the median life expectancy for someone with AIDS in the pre-ART era - advanced HIV disease, no treatment - was less than 2 years.
I think we'd all agree that this grim prognosis is simply unacceptable if we have an available effective treatment we're not using.
|
|
| |
| |
|
|
|
